LAB International initiates patient enrollment in the extension of its phase IIb Fentanyl TAIFUN(R) trial



    
                         New Board Member Appointed
    

    MONTREAL, Jan. 31 /CNW Telbec/ - LAB International Inc. (TSX: LAB,
Frankfurt: LD9.F, XETRA: LD9.DE) ("LAB"), a drug development company focused
on developing therapies for the inhalation and pain markets, today announced
enrollment of the first patient in the extension arm of its Fentanyl TAIFUN(R)
Phase IIb clinical trial. Fentanyl TAIFUN(R) is a fast-acting Fentanyl
formulation delivered using the Company's TAIFUN(R) dry powder inhaler
platform.
    Phase IIb for Fentanyl TAIFUN(R) is a multi-centered, multinational
clinical trial in cancer patients with severe persistent pain on maintenance
opioid therapy. The first part of the trial is a single arm, open-label dose
titration to evaluate the effective individual dose for significant pain
relief with Fentanyl TAIFUN(R) in the treatment of breakthrough cancer pain.
The required enrolment of 32 patients is expected to be completed by the end
of this quarter. The second part is randomized, double-blind, cross-over and
placebo controlled, continuing with a total of 28 patients from the open-label
part and is expected to be completed before the end of the second quarter of
2007.
    "We are extremely enthusiastic about our product and want to finish the
second part of the trial as quickly as possible. We are confident that
Fentanyl TAIFUN(R) will continue to demonstrate the same superior therapeutic
properties, significant and rapid pain relief previously demonstrated. We
strongly believe that Fentanyl TAIFUN(R) will provide these cancer patients
with a superior therapeutic alternative for the treatment of their pain
attacks." said Dr. Halvor Jaeger, Chief Executive Officer of LAB
International.
    The Company is also pleased to announce the appointment of Dr. Robert O.
(Bill) Williams III to its Board of Directors. Dr. Williams was the co-founder
and President of PharmaForm L.LC. Dr. Williams is the Johnson & Johnson
Centennial Professor of Pharmaceutics at the College of Pharmacy, University
of Texas at Austin. Dr Williams is a vastly published author in the fields of
pharmaceutical technology and drug delivery with research interests in the
development of novel drug delivery systems for oral, pulmonary, nasal,
injectable, buccal and topical applications. He is also an inventor on
numerous patents and patent applications.
    Chronic pain associated with advanced cancer is commonly treated with
strong opioid analgesics, such as fentanyl. Breakthrough pain episodes are
sudden and intense flares of pain that "break through" a long-acting
continuous treatment, such as a transdermal patch or a slow release tablet.
Break-through pain episodes are common in cancer patients, often occurring
several times a day.

    About LAB International

    LAB International (LAB Pharma and LAB Research) is an integrated drug
development company. LAB Pharma is focused on the growing multi-billion dollar
inhalation market. Its lead product, for the treatment of breakthrough cancer
pain, is a fast-acting Fentanyl formulation delivered using the Company's
TAIFUN(R) dry powder inhaler platform. Its pipeline also includes therapeutics
for asthma, COPD, and growth hormone deficiencies. LAB Research is a
profitable and growing contract research services division supporting its
clients base from state-of-the-art facilities in Canada, the US, Denmark and
Hungary.
    LAB's common shares trade on The Toronto Stock Exchange ("TSX") under the
symbol "LAB", on the Frankfurt Regulated Unofficial Market under the symbol
"LD9.F" and on XETRA under the symbol "LD9.DE" with 82.3 million shares
outstanding.

    This news release contains certain forward-looking statements that
reflect the current views and/or expectations of LAB International Inc. with
respect to its performance, business and future events. Such statements are
subject to a number of risks, uncertainties and assumptions. Actual results
and events may vary significantly.
    %SEDAR: 00003466EF




For further information:

For further information: visit LAB's website at www.labinc.ca, or
contact: Frédéric Dumais, Vice-President, Investor Relations, (514) 315-3330
ext. 106, Fax: (514) 315-3325, dumaisf@labinc.ca

Organization Profile

Akela Pharma Inc

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890